Clinical trial · Observational
Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
NCT06422247CI-TRIAL-00090556completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to describe the therapeutic practices and the prognosis of patients with relapsed or refractory peripheral T-cell lymphoma in Japan
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Peripheral T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Systemic therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Relapsed or refractory peripheral T-cell lymphoma initiating second-line systemic therapy
- interventionNames
- Drug: Systemic therapy
Primary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- From baseline until date of death from any cause or last known alive date, assessed up to 6 years
Secondary outcomes (5)
- measure
- Participant baseline demographics
- timeFrame
- Baseline
- measure
- Participant baseline clinical characteristics
- timeFrame
- Baseline
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female participants with a confirmed diagnosis of the specific subtypes of peripheral T-cell lymphoma (PTCL) according to The World Health Organization (WHO) classification of lymphoid neoplasm, 4th edition defined by WHO and International Agency for Research on Cancer (IARC). * Participates aged ≥18 years of age at diagnosis of PTCL. * Participates who have been treated with a systemic therapy for PTCL and have initiated a systemic therapy as a second-line therapy for relapsed or refractory PTCL between April 1, 2018 and March 31, 2023. Exclusion Criteria: * Participates who have medical history of peripheral T-cell lymphoma (PTCL) treatment by unapproved drug in Japan as of 31 March 2024 or off-label drug for PTCL in Japan as of 31 March 2024. * Participates who have medical history of participation to a separately defined registration study for regulatory approval in PTCL. * Participates who have medical history of PTCL treatment in a separately defined clinical study with intervention by on-label regimen for PTCL. * Participates judged to be inappropriate for enrollment in this study by the site investigator.
References
Publications (0)
Data not yet available
No reference posted for this study.